IRD (Opus Genetics) YoY EBITDA Growth: 51.43% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRD Opus Genetics Inc IRD
20 GF Score
Price $3.76
GF Value $0.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Opus Genetics YoY EBITDA Growth?

Opus Genetics IRD -3.09% 20 YoY EBITDA Growth is 51.43% as of Jun. 2026. GuruFocus rates IRD with a GF Score™ of 20/100 and a GF Value™ of $0.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Opus Genetics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 51.43%.

Opus Genetics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.07.

Opus Genetics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Opus Genetics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics YoY EBITDA Growth Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -0.16 123.16 -145.25 -438.25 64.10

Opus Genetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.49 14.58 83.75 -271.64 51.43
IRD
20GF Score
Opus Genetics Inc IRD
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Opus Genetics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.773--2.153)/ | -2.153 |
=64.10 %

Opus Genetics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.068--0.14)/ | -0.14 |
=51.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 51.43% mean?
Opus Genetics (IRD) has a YoY EBITDA Growth of 51.43% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Opus Genetics and its competitors.
Is Opus Genetics' YoY EBITDA Growth too high?
Opus Genetics' current YoY EBITDA Growth is 51.43%. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' YoY EBITDA Growth compare to TTRX and VRXA?
Opus Genetics' YoY EBITDA Growth of 51.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Opus Genetics and its competitors. Opus Genetics's current YoY EBITDA Growth is 51.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $3.76 — trading 1196.6% above its estimated fair value. The current YoY EBITDA Growth is 51.43%. Opus Genetics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Opus Genetics (IRD), the current YoY EBITDA Growth is 51.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.76 is trading 1196.6% above its estimated GF Value™ of $0.29. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • YoY EBITDA Growth: 51.43%
  • GF Value™: $0.29 vs. price of $3.76 (1196.6% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score

Get the complete analysis for IRD

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.76
Price
$0.29
GF Value